Celgene Clinical Trials Information

Clinical trials are research that involve patients. Joining a clinical trial allows a patient to become a partner in the search for new and better ways to prevent, screen for or treat a disease.

Celgene is currently conducting clinical trials worldwide for a range of diseases. Patients who participate will be given full disclosure on the nature of the study, the therapies and tests they may have, and the possible risks and benefits.

Why are clinical trials important?

Clinical trials are part of clinical research and at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease. By participating in a clinical trial you may be helping others by contributing to medical research.

Celgene Sponsored Clinical Trials Now Enrolling

Triple Negative Metastatic Breast Cancer

The tnAcity study has been developed to see what combination of chemotherapy medicines may work best to treat triple negative metastatic breast cancer (TNMBC). The drug being studied is called albumin bound paclitaxel- nab Paclitaxel (nab-PAK-li-TAK-sel). 790 women are expected to participate in the tnAcity study. Through the study, researchers aim to discover how long the cancer is prevented from growing after a person takes albumin bound paclitaxel and how much of the cancer shrinks as a result. To learn more please, click here.

Follicular or Marginal Zone Lymphoma

The AUGMENT™ Research Study will measure how well an investigational medicine called lenalidomide works when given with rituximab to see if it can control the disease and increase the length of response compared with rituximab alone in previously treated patients. Approximately 350 patients from around the world will participate in this study.

Follicular or Marginal Zone or Mantle Cell Lymphoma

The MAGNIFY Study will measure how well an investigational medicine called lenalidomide works when given with rituximab over a long period of time in previously treated patients. Researchers want to learn if this treatment can control the disease and increase the length of response when compared with rituximab alone. Up to 500 patients in the US will participate in this study. To learn more about this trial, please click here.

Acute Myeloid Leukemia

The QUAZAR® Acute Myeloid Leukemia (AML) study has been developed to investigate how well a research medicine called CC-486 (Oral Azacitidine) in combination with best supportive care works as a maintenance therapy in AML patients who have achieved Complete Remission after undergoing induction therapy with or without consolidation therapies. The primary goal of the study is to see if CC-486 prevents/prolongs the relapse of the AML disease and improve survival. Approximately 460 patients from around the world will participate in this study. To learn more about this trial, please click here.

Myelodysplastic Syndrome (MDS)

The QUAZAR® Myelodysplastic Syndromes (MDS) study has been developed to investigate how well a research medicine called CC-486 (Oral Azacitidine) in combination with best supportive care works on lower-risk MDS patients who rely on red blood cell transfusions and have low platelets. The main goals of the study are to see if CC-486 increases red blood cell counts so blood transfusions are not needed and to improve survival. Approximately 386 patients from around the world will participate in this study. To learn more about this trial, please click here.

Did not find what you’re looking for? Click here to see the latest information on clinical trials.